Trooperstocks
4 días hace
$COEP News: Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement
Aim to create the largest publicly-traded, Dogecoin-focused mining company in the world Coeptis to spin out biopharmaceutical operations
April 25, 2025 08:33 ET
| Source: Coeptis Therapeutics
WEXFORD, Pa., April 25, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq; COEP) (“Coeptis” or the “Company”), a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune and infectious diseases, and Z Squared Inc. (“Z Squared”), a Dogecoin mining company, today announced they have entered into a definitive merger agreement for a business combination that will result in Z Squared becoming a wholly-owned subsidiary of Coeptis. Under the terms of the merger agreement, a wholly-owned subsidiary of Coeptis will merge with and into Z Squared and the holders of the outstanding Z Squared shares will receive equity in Coeptis in exchange for 9,000 U.S. based dogecoin mining machines at closing. The Boards of Directors of both Coeptis and Z Squared have approved the proposed merger, which is subject to customary closing conditions, including receipt of all regulatory approvals, continued Nasdaq listing and the approval of the proposed merger by Coeptis’ and Z Squared’s shareholders. In connection with the merger, Coeptis intends to spin out its biopharmaceutical operations, and continue to operate those operations separate from Coeptis after the merger. The technology operations will remain in the Company after the merger. Assuming all conditions to closing are satisfied, the close of the transaction is anticipated to occur in the third quarter of 2025. It is anticipated that Coeptis will be rebranded and operate as Z Squared, Inc., and is expected to list on the Nasdaq Capital Market.
The combined Company will focus on advancing Z Squared’s digital asset mining expertise, which focuses primarily on generating Dogecoin (“DOGE”), along with other digital assets. DOGE has a market cap of over $20B and its native blockchain network’s operating mechanism provides proof-of-work (PoW) DOGE rewards to the owners of digital asset mining machines, highly sophisticated computers which complete complex mathematical equations to process and record transactions on the network.
The surviving entity will be led by Z Squared executives, David Halabu as Chief Executive Officer and Michelle Burke as Chief Operating Officer. Current Coeptis President and Chief Executive Officer, Dave Mehalick, will exit from the Board of Directors upon closing. Prior to serving as Chief Executive Officer of Z Squared, David Halabu was the founder and Managing Partner of multi-vertical alternative investment firm, Group 10 Capital Management.
Michelle Burke was most recently the Chief Executive Officer at the pre-eminent digital asset mining company, Minting Dome Inc.
"We are excited to take this step towards our goal of creating the largest publicly-traded company in the United States primarily focused on DOGE mining," said David Halabu. "We’re proud of our strategy to bring retail and institutional audiences alike in the public markets a focused exposure to a DOGE asset that currently has over $20B in market capitalization. We believe we have assembled a stellar team that has the requisite expertise and infrastructure."
"We are excited to bring this opportunity to our shareholders to become involved in the Dogecoin market space, while at the same time being able to remain involved in our biopharmaceutical operations as a result of the contemplated spin out of those operations at closing," said Dave Mehalick. "I’ve been deeply engaged in the evolution of blockchain infrastructure and am aligned with the direction the new leadership intends to take the Company."
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
Coeptis’ therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, Coeptis has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, Coeptis is dedicated to advancing its mission within the regulatory framework set forth by the Food and Drug Administration, ensuring that all activities align with the highest standards of compliance and patient care. For more information on Coeptis and its lines of business, visit https://coeptistx.com About Z Squared Inc.
Z Squared Inc. is a digital asset mining company, focused primarily on the generation of Dogecoin (DOGE), along with other digital assets such as Litecoin and other altcoins. Z Squared aims to unlock gainful investor mining exposure to DOGE, its $20B market cap, and the robust business of altcoin compute mining.
Additional Information and Where to Find It
In connection with the merger agreement and the proposed business combination, Coeptis intends to file with the SEC a Registration Statement, which will include a preliminary proxy statement/prospectus and a proxy statement/prospectus. Coeptis’ stockholders and other interested persons are advised to read, when available, the preliminary proxy statement/prospectus and the amendments thereto and the definitive proxy statement/prospectus and documents incorporated by reference therein filed in connection with the business combination, as these materials will contain important information about Coeptis, Z Squared, the merger agreement, the business combination and the spin out. When available, the definitive proxy statement/prospectus and other relevant materials for the business combination will be mailed to stockholders of Coeptis and Z Squared as of a record date to be established for voting on the business combination and spin out. Stockholders of Coeptis and Z Squared will also be able to obtain copies of the Registration Statement, the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s web site at www.sec.gov.
Participants in the Solicitation
Coeptis, Z Squared and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Coeptis’ and Z Squared’s stockholders with respect to the proposed business combination and spin out. Investors and securityholders may obtain more detailed information regarding the names and interests in the business combination of the directors and officers of each of Coeptis and Z Squared in such companies’ respective filings with the SEC, including the Registration Statement.
No Offer or Solicitation
This press release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed business combination or spin out. This press release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. These statements are subject to significant uncertainties and risks including, but not limited, to those risks contained in reports filed by Coeptis with the Securities and Exchange Commission (the "SEC"). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
Trooperstocks
2 meses hace
News: Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License
GetNews - TGAM - GetNews - Fri Mar 14, 4:16AM CDT
COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities
Coeptis Inc. (Nasdaq: COEP) has taken a bold step forward in the fight against cancer by securing exclusive worldwide development and commercialization rights to the groundbreaking GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform. This acquisition positions Coeptis as a leader in innovative oncology solutions, making it an attractive opportunity for traders and investors looking for high-growth potential in the biotech sector.
What Makes GEAR-NK a Game-Changer?
GEAR-NK (Gene-Edited Antibody Resistant Natural Killer Cells) represents a first-in-class approach to optimizing cancer immunotherapy. Unlike traditional NK cells that may be neutralized when used alongside monoclonal antibodies (mAbs), GEAR-NK cells are engineered to resist antibody-based depletion. This advancement allows for a synergistic effect, enhancing the potency and efficacy of combination cancer treatments.
By integrating GEAR technology into hematopoietic stem cells (HSCs), Coeptis is also exploring improved outcomes for bone marrow transplants, offering potential breakthroughs in treating hematologic malignancies. This pioneering approach has the potential to significantly enhance patient response rates and expand the market for Coeptis’ next-generation therapies.
Expert Endorsement and Market Potential
Dr. Evren Alici, a renowned expert from Karolinska Institutet and a member of COEP’s Scientific Advisory Board, emphasized that GEAR-based immunotherapy offers a differentiated and highly promising strategy in cancer treatment. Specifically, the ability to co-administer NK cells with CD38-targeting mAbs for multiple myeloma treatment while minimizing “on-target/off-tumor” effects could redefine how antibody-based therapies are delivered.
Coeptis CEO Dave Mehalick stated, “The market potential of GEAR is extensive and is driven by therapeutic need. GEAR, integrated into our allogeneic cellular immunotherapy platform, has the potential to provide a beneficial, cost-effective therapeutic option available to all patients in need.”
Strategic Expansion with GEAR Therapeutics, Inc.
To accelerate the commercialization of the GEAR platform, Coeptis has established GEAR Therapeutics, Inc., a majority-owned subsidiary dedicated to advancing GEAR-based cell therapies into human clinical trials. This move underscores Coeptis’ commitment to maximizing the value of its newly acquired technology and positioning itself as a dominant player in next-generation cancer immunotherapies.
Potential Investment Opportunity in COEP
For investors, COEP presents a compelling growth opportunity in the rapidly evolving immunotherapy market. With exclusive rights to a novel cell therapy platform, strategic partnerships with globally recognized institutions like Karolinska Institutet, and a leadership team focused on clinical execution, Coeptis is well-positioned for long-term success.
As Coeptis progresses towards clinical proof-of-concept studies for GEAR-NK, traders and investors should keep a close watch on COEP. The potential for breakthrough therapies, combined with the expanding market for immune cell therapies, makes this stock an exciting prospect in the biotechnology sector.
Summary
Coeptis’ exclusive GEAR license signals a significant advancement in immunotherapy and a prime opportunity for investors looking to capitalize on biotech innovation. As the company continues to expand its pipeline and advance towards clinical trials, COEP’s stock could become a high-value asset in the healthcare sector. Stay tuned for further developments as Coeptis transforms cancer treatment with its pioneering technologies.
About VyGen-Bio, Inc.
VyGen-Bio, a majority-owned subsidiary of Vycellix, Inc., operates in both Florida and Stockholm, Sweden. Its technology platforms were developed by leading researchers at Karolinska Institutet and are part of NextGenNK, an internationally recognized center for NK cell-based cancer immunotherapies.
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Other notable biotech stocks to keep on top of radar include (NASDAQ: VRTX) Vertex Pharmaceuticals Incorporated), (NASDAQ: REGN) Regeneron Pharmaceuticals, Inc., (NASDAQ: ALNY) Alnylam Pharmaceuticals, Inc., (NASDAQ: RPRX) Royalty Pharma plc, (NASDAQ: SMMT) Summit Therapeutics Inc.
For more details, visit www.VyGen-Bio.com.
Source: https://finance.yahoo.com/news/coeptis-therapeutics-secures-worldwide-development-123400980.html
Trooperstocks
2 meses hace
News: Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline
Coeptis Therapeutics
Tue, March 11, 2025 at 8:34 AM EDT
In This Article:
COEP
+4.51%
COEPW
+56.40%
Coeptis Therapeutics
• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities.
WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced it has successfully licensed exclusive worldwide development and commercialization rights to the GEAR™ (Gene Edited Antibody Resistant) Cell Therapy Platform, representing a first-in-class approach to modifying potent cancer-targeting immune cells to optimize the likelihood of deep remission in patients with hematologic malignancies and other cancers. Coeptis had previously held limited co-development rights to GEAR. As part of this exclusive GEAR license agreement with VyGen-Bio, Inc., Coeptis has formed a new majority-owned subsidiary, GEAR Therapeutics, Inc., with the mission to advance GEAR-based cell therapy towards human proof-of-concept studies to initially evaluate GEAR-modified natural killer cells (GEAR-NK) for the treatment of a broad range of cancers and other therapeutic modalities.
How Is GEAR-NK Expected to Enhance Current Blood Cancer Treatments?
Gene-Edited Antibody Resistant NK cells (GEAR-NK) are being developed as novel cancer strategy to allow for modified NK cells to be co-administered with targeted monoclonal antibodies (“mAbs”), which in the absence of the GEAR-NK would otherwise be neutralized/eradicated by mAb therapy due to a common receptor shared by both malignant cells and NK cells. GEAR-NK represents a combination cancer therapy with the potential for significantly improved outcomes for patients. The GEAR platform also holds the potential to modify hematopoietic stems cells (HSCs) in combination with mAbs to improve bone marrow transplant outcomes in the treatment of a broad range of hematological malignancies.
According to COEP Scientific Advisory Board member, Evren Alici, M.D., Ph.D., “GEAR-based immunotherapy represents a differentiated approach to potentially optimize and enhance current antibody-based cancer therapy, such as CD38 mAbs for the treatment of multiple myeloma. By leveraging specific sites, we aim to enable GEAR-modified immune cells, NK cells in this instance, to be co-administered in combination with antibodies in a manner that largely avoids undesired ‘on target/off tumor effects’ on a plethora of combination or retargeting therapies. The encouraging pre-clinical proof-of-concept data lead us to believe a GEAR-NK strategy holds the potential to advantageously eliminate or reduce the risk of NK cell fratricide while improving clinical benefit.” Dr. Alici serves as head of the cell & gene therapy group at Sweden’s renowned Karolinska Institutet.
Dave Mehalick, CEO of COEPTIS, expressed excitement, saying, “This expanded ownership of the GEAR technology is a major achievement for COEPTIS. The market potential of GEAR is extensive and is driven by therapeutic need. GEAR, integrated into our allogeneic cellular immunotherapy platform, has the potential to provide a beneficial, cost-effective therapeutic option available to all patients in need.”
About VyGen-Bio, Inc.
With operations in Florida, USA and Stockholm, Sweden, VyGen-Bio is a majority-owned subsidiary of Vycellix, Inc (www.Vycellix.com). The Company’s platforms were discovered by research scientists based at the Cell & Gene Therapy Group at Karolinska Institutet (KI), Sweden. Additionally, VyGen-Bio is a member-partner in “NextGenNK”, the international Competence Center for the development of next-generation NK cell-based cancer immunotherapies based at KI and funded by Sweden’s innovations agency, Vinnova. KI is globally recognized for its Nobel Assembly, which awards the Nobel Prize in Physiology or Medicine. Website: www.VyGen-Bio.com
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
Trooperstocks
2 meses hace
$COEP NEWS: COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan
Coeptis Therapeutics
Fri, March 7, 2025 at 8:37 AM EST
In This Article:
COEP, COEPW, BURU, BURUW
Coeptis Therapeutics
Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security Sectors
WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS’ NexGenAI Affiliates Network “NexGen” and NUBURU, Inc. “NUBURU” (NYSE: BURU), a leading innovator in high-power blue laser technology. This collaboration is a pivotal component of COEPTIS’ strategic position in technology and Artificial Intelligence and NUBURU’s comprehensive Transformation Plan, spearheaded by Executive Chairman Alessandro Zamboni, aimed at enhancing operational efficiency and revamping the company’s business model entering defense-tech, security, and operational resilience solutions.
NexGen will be assisting NUBURU in its Transformation Plan by using its cutting-edge AI-driven capabilities and robotic process automation. NUBURU is anticipated to play an important role as a tech and business growth enabler of its subsidiaries and the other strategic ventures and investments leveraging the existing know-how regarding blue-laser technology and additional expertise to be brought by their new management team.
Dave Mehalick, CEO of COEPTIS stated, “Partnering with NUBURU marks a significant step in COEPTIS' journey toward pioneering innovative technology solutions. By harnessing the power of NexGen’s AI-driven capabilities, we are poised to not only enhance our own operational efficiencies but also redefine how businesses engage with their clients in the rapidly evolving defense and security landscape. This collaboration underscores our commitment to fostering growth through advanced technological integrations.”
The partnership between NexGen and NUBURU exemplifies NUBURU’s strategy to revolutionize its planned marketing and B2B sales processes, particularly within the defense and security sector, where the company anticipates significant opportunities for growth leveraging its laser-technology expertise and experience and recently announced investments.
Alessandro Zamboni Executive Chairman of NUBURU stated, “Our partnership with COEPTIS’ NexGenAI Affiliates Network is an exciting step forward in executing our Transformation Plan. By integrating cutting-edge AI-driven capabilities and robotic process automation into our future redesigned marketing & sales processes, we are not only streamlining our business but also creating a foundation for an innovative business model. This strategic collaboration aligns perfectly with our vision of establishing synergies across our acquisitions and enhancing our market presence in the defense and security sectors, where our laser-technology expertise can play an important role”.
NexGen’s advanced platform utilizes sophisticated AI algorithms and data analytics to optimize marketing strategies, enhance customer engagement, and implement operational efficiencies. This collaboration marks an essential milestone in NUBURU's broader goal of fostering an ecosystem where technology serves as a catalyst for growth and innovation.
“Incorporating NexGen's transformative technologies will allow us to elevate our future marketing strategies as we implement or Transformation Plan,” added Zamboni. “We believe that by positioning NUBURU as a blitz-scaling enabler of its anticipated business lines, by leveraging the adoption of exponential technologies, we can significantly enhance our value proposition to future end-clients and stakeholders alike.”
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com
About NexGenAI Affiliates Network
NexGenAI Affiliates Network is a state-of-the-art AI-powered affiliate marketing platform designed to streamline marketing efforts through automation and advanced analytics. Owned by COEPTIS, Inc. (NASDAQ: COEP), NexGenAI Affiliates Network empowers individuals and businesses to optimize their affiliate campaigns and maximize revenue through AI-driven content distribution, automated email outreach, and social media integration. For more information on this partnership and how it can benefit businesses and affiliates, visit https://nexgenaiaffiliates.io/.
About NUBURU
NUBURU, Inc. was founded in 2015 as a developer and manufacturer of industrial blue laser technology that is transforming the speed and quality of laser-based manufacturing. Under its new management team led by Executive Chairman Alessandro Zamboni, NUBURU is executing a comprehensive growth and diversification strategy, expanding into complementary domains such as defense-tech, security, and operational resilience solutions. Headquartered in Centennial, Colorado, NUBURU is leveraging strategic partnerships and acquisitions to accelerate growth in high-value sectors. For more information, visit www.nuburu.net.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
COEPTIS, INC. (NASDAQ: COEP)
Investor Relations: IR@coeptistx.com
Website: https://coeptistx.com
NexGenAI Affiliates Network: https://nexgenaiaffiliates.io
NUBURU, Inc. (NYSE: BURU)
Investor Relations: alessandro.zamboni@nuburu.net
Media Contact: press@nuburu.net
Website: www.nuburu.net
Trooperstocks
2 meses hace
$COEP in Today's News: COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network
The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and Blockchain Technology
February 20, 2025 09:00 ET
| Source: Coeptis Therapeutics
WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS’ NexGenAI Affiliates Network and Arketyp Valu, a prominent developer within the open-source Verus Project, which has recently achieved a market capitalization exceeding $500 million. This collaboration aims to integrate NexGenAI's advanced digital marketing solutions into the highly anticipated ValuSocial platform, harnessing the power of Verus Coin and its scalable Public Blockchains as a Service (PBaaS).
The innovative ValuSocial platform is set to transform the landscape of digital marketing by offering users a fully immersive environment where they can leverage NexGenAI's pioneering solutions. This integration will empower individuals and businesses to launch targeted digital campaigns that combine cutting-edge marketing strategies with the security and scalability of blockchain technology, enhancing engagement through seamless interaction and digital tokens.
“As CEO of Arketyp Valu, I am thrilled to lead this partnership and incorporate NexGenAI’s state-of-the-art tools into our upcoming ValuSocial platform,” stated Nicholas Lyons, CEO of Arketyp Valu. “This collaboration effectively merges the latest in digital marketing innovation with the reliable and scalable framework of the Verus network, heralding a new era of global digital engagement.”
Dave Mehalick, CEO of COEPTIS, expressed enthusiasm for the collaboration, saying, “Our tools are designed to empower businesses in the digital age, and their integration on the ValuSocial platform represents a transformative advancement. By combining our expertise with Arketyp Valu’s groundbreaking offerings, we are laying the groundwork for a decentralized, interconnected digital ecosystem that delivers value to users and businesses around the world.”
This partnership showcases the commitment of both COEPTIS’ NexGenAI Affiliates Network and Arketyp Valu to drive innovation while redefining digital marketing capabilities. The ValuSocial platform, built on the secure foundations of the Verus Project, will deliver next-generation marketing solutions, allowing users to access advanced tools within a compliant and scalable blockchain environment.
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com
About Arketyp Valu
Arketyp Valu is involved with the Verus project, which includes the development and promotion of Verus Coin. Verus Coin is a cryptocurrency that operates on the Verus blockchain, focusing on features such as privacy, security, and scalability.
The Verus project aims to create a decentralized ecosystem that empowers users while providing tools for developers to build applications that enhance the utility of the cryptocurrency. As a contributor and developer, Arketyp Valu plays a part in advancing the technology and applications associated with Verus Coin, helping to support its growth and adoption within the broader cryptocurrency community.
About NexGenAI Affiliates Network
NexGenAI Affiliates Network is a state-of-the-art AI-powered affiliate marketing platform designed to streamline marketing efforts through automation and advanced analytics. Owned by Coeptis Therapeutics Holdings Inc., NexGenAI Affiliates Network empowers individuals and businesses to optimize their affiliate campaigns and maximize revenue through AI-driven content distribution, automated email outreach, and social media integration. For more information on this partnership and how it can benefit businesses and affiliates, visit https://nexgenaiaffiliates.io/.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
Trooperstocks
2 meses hace
NEWS: COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
Coeptis Therapeutics
Thu, February 20, 2025 at 7:27 AM EST
In This Article: COEP, COEPW
Coeptis Therapeutics
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry
WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is thrilled to announce a partnership between COEPTIS’ NexGenAI Affiliates Network and MarketLeverage, a leading digital advertising firm and affiliate network. This collaboration aims to redefine affiliate marketing by integrating cutting-edge AI technology with performance-based strategies.
With MarketLeverage’s extensive industry expertise and NexGenAI Affiliates Network’s innovative AI-powered platform, this collaboration will empower affiliates, brands, and marketers with advanced automation, data-driven insights, and seamless campaign optimization. MarketLeverage currently works with 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry. This strategic partnership will drive high-quality traffic, increase conversions, and enhance overall marketing efficiency.
“This partnership marks a significant step in transforming digital marketing by integrating AI with performance-based strategies,” said Shane Hackett, CEO of MarketLeverage. “By combining our extensive network of advertisers and affiliates with NexGenAI’s automated tools, we will provide businesses with unprecedented opportunities to scale their marketing efforts. The future of affiliate marketing is in automation and AI-driven insights, and we are excited to lead this transformation.”
NexGenAI Affiliates Network, recently acquired by Coeptis Therapeutics Holdings Inc., has quickly established itself as a leader in AI-powered marketing automation. The platform enables affiliates to earn commissions through automated content distribution, social media sharing, and targeted email campaigns, leveraging AI to optimize performance in real-time.
“Our mission has always been to empower marketers with the latest AI-driven solutions,” said Dave Mehalick, CEO of Coeptis Therapeutics Holdings Inc. “Partnering with MarketLeverage will accelerate our reach and provide affiliates and brands with an unmatched ability to monetize digital content and drive engagement. With MarketLeverage’s vast network and our AI-powered tools, we are creating a new frontier in performance marketing.”
Through this collaboration, affiliates will gain access to an enhanced suite of tools, including AI-driven campaign management, predictive analytics, and automated outreach capabilities. Advertisers will benefit from increased visibility, higher conversion rates, and improved return on investment.
The partnership between MarketLeverage and NexGenAI Affiliates Network underscores a shared commitment to innovation and efficiency in the digital marketing space. As AI continues to shape the future of affiliate marketing, this alliance ensures that brands, affiliates, and publishers stay ahead of the curve. As COEPTIS has entered the artificial intelligence marketplace, the market size will grow from $27.83 billion in 2024 to $35.54 billion in 2025 at a compound annual growth rate (CAGR) of 27.7%. The artificial intelligence in marketing market size is expected to see exponential growth in the next few years. It will grow to $106.54 billion in 2029 at a compound annual growth rate (CAGR) of 31.6% (sited from https://www.thebusinessresearchcompany.com).
For more information on this partnership and how it can benefit businesses and affiliates, visit https://www.marketleverage.com/ and https://nexgenaiaffiliates.io/.
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com
About MarketLeverage
MarketLeverage is an award-winning digital advertising firm specializing in performance marketing and affiliate campaign management. With over two decades of experience, the company helps brands scale their digital presence through targeted lead generation and strategic partnerships. MarketLeverage has been recognized as an INC 100 Advertising Agency and among the Fortune 5000 Fastest Growing Private Companies. MarketLeverage currently works with 5,500 advertisers and 55,000 publishers to drive impactful marketing campaigns.
About NexGenAI Affiliates Network
NexGenAI Affiliates Network is a state-of-the-art AI-powered affiliate marketing platform designed to streamline marketing efforts through automation and advanced analytics. Owned by Coeptis Therapeutics Holdings Inc., NexGenAI Affiliates Network empowers individuals and businesses to optimize their affiliate campaigns and maximize revenue through AI-driven content distribution, automated email outreach, and social media integration.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
Trooperstocks
2 meses hace
$COEP NEWS: COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing
Coeptis Therapeutics
Wed, February 19, 2025 at 4:00 PM EST 7 min read
In This Article: COEP, COEPW
Coeptis Therapeutics
This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry
WEXFORD, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is thrilled to announce a partnership between COEPTIS’ NexGenAI Affiliates Network and MarketLeverage, a leading digital advertising firm and affiliate network. This collaboration aims to redefine affiliate marketing by integrating cutting-edge AI technology with performance-based strategies.
With MarketLeverage’s extensive industry expertise and NexGenAI Affiliates Network’s innovative AI-powered platform, this collaboration will empower affiliates, brands, and marketers with advanced automation, data-driven insights, and seamless campaign optimization. MarketLeverage currently works with 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industry. This strategic partnership will drive high-quality traffic, increase conversions, and enhance overall marketing efficiency.
“This partnership marks a significant step in transforming digital marketing by integrating AI with performance-based strategies,” said Shane Hackett, CEO of MarketLeverage. “By combining our extensive network of advertisers and affiliates with NexGenAI’s automated tools, we will provide businesses with unprecedented opportunities to scale their marketing efforts. The future of affiliate marketing is in automation and AI-driven insights, and we are excited to lead this transformation.”
NexGenAI Affiliates Network, recently acquired by Coeptis Therapeutics Holdings Inc., has quickly established itself as a leader in AI-powered marketing automation. The platform enables affiliates to earn commissions through automated content distribution, social media sharing, and targeted email campaigns, leveraging AI to optimize performance in real-time.
“Our mission has always been to empower marketers with the latest AI-driven solutions,” said Dave Mehalick, CEO of Coeptis Therapeutics Holdings Inc. “Partnering with MarketLeverage will accelerate our reach and provide affiliates and brands with an unmatched ability to monetize digital content and drive engagement. With MarketLeverage’s vast network and our AI-powered tools, we are creating a new frontier in performance marketing.”
Through this collaboration, affiliates will gain access to an enhanced suite of tools, including AI-driven campaign management, predictive analytics, and automated outreach capabilities. Advertisers will benefit from increased visibility, higher conversion rates, and improved return on investment.
The partnership between MarketLeverage and NexGenAI Affiliates Network underscores a shared commitment to innovation and efficiency in the digital marketing space. As AI continues to shape the future of affiliate marketing, this alliance ensures that brands, affiliates, and publishers stay ahead of the curve. As COEPTIS has entered the artificial intelligence marketplace, the market size will grow from $27.83 billion in 2024 to $35.54 billion in 2025 at a compound annual growth rate (CAGR) of 27.7%. The artificial intelligence in marketing market size is expected to see exponential growth in the next few years. It will grow to $106.54 billion in 2029 at a compound annual growth rate (CAGR) of 31.6% (sited from https://www.thebusinessresearchcompany.com).
For more information on this partnership and how it can benefit businesses and affiliates, visit https://www.marketleverage.com/ and https://nexgenaiaffiliates.io/.
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com
About MarketLeverage
MarketLeverage is an award-winning digital advertising firm specializing in performance marketing and affiliate campaign management. With over two decades of experience, the company helps brands scale their digital presence through targeted lead generation and strategic partnerships. MarketLeverage has been recognized as an INC 100 Advertising Agency and among the Fortune 5000 Fastest Growing Private Companies. MarketLeverage currently works with 5,500 advertisers and 55,000 publishers to drive impactful marketing campaigns.
About NexGenAI Affiliates Network
NexGenAI Affiliates Network is a state-of-the-art AI-powered affiliate marketing platform designed to streamline marketing efforts through automation and advanced analytics. Owned by Coeptis Therapeutics Holdings Inc., NexGenAI Affiliates Network empowers individuals and businesses to optimize their affiliate campaigns and maximize revenue through AI-driven content distribution, automated email outreach, and social media integration.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
Trooperstocks
2 meses hace
NEWS: $COEP COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups
Coeptis Therapeutic
Thu, February 13, 2025 at 8:39 AM EST
In This Article: COEP +4.41%
COEPW - Coeptis Therapeutics
WEXFORD, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the launch of COEP Venture Group, a newly established investment arm dedicated to funding and accelerating technology startups specializing in Artificial Intelligence (AI), Robotic Process Automation (RPA), and AI Agents.
COEP Venture Group aims to identify, invest in, and support high-potential startups shaping the future of automation, intelligent systems, and AI-driven enterprise solutions. By providing capital, strategic mentorship, and access to industry networks, COEP Venture Group seeks to drive technological advancements that enhance business efficiency, decision-making, and automation across multiple industries.
Empowering the Future of AI & Automation
"The launch of COEP Venture Group aligns with our vision of investing in disruptive technologies that redefine industries," said Dave Mehalick, CEO of Coeptis Therapeutics Holdings Inc. “AI-driven automation and intelligent agents are transforming the way businesses operate. Through COEP Venture Group, we are committed to supporting pioneering startups at the forefront of AI and RPA innovation,” continued Mr. Mehalick.
In addition, COEP Venture Group will leverage NexGenAI Solutions Group, which powers its latest acquisition, NexGenAI Affiliates Group, to provide marketing services to portfolio companies. This initiative ensures that startups receive not only funding but also strategic exposure and market positioning, allowing them to scale rapidly and successfully execute their business plans.
Leadership & Strategic Vision
COEP Venture Group will benefit from the expertise of Michael Woloshin, a seasoned entrepreneur with deep experience in technology, AI, and marketing automation. Michael Woloshin was the co-founder of Recruiter.com and the founder of NexGenAI Solutions Group, which powers COEP’s latest acquisition, NexGenAI Affiliates Group, where he built the technology platform enabling marketing and business automation. His leadership and insights will drive COEP Venture Group’s mission to foster innovation and expand market opportunities for emerging technology companies.
Investment Focus
COEP Venture Group will target high-growth startups that align with its investment strategy, including:
Artificial Intelligence (AI)– Advanced machine learning models, predictive analytics, and AI-driven enterprise solutions.
Robotic Process Automation (RPA)– AI-powered automation to streamline workflows, enhance business operations, and reduce inefficiencies.
AI Agents & Intelligent Systems– Autonomous AI-powered assistants and decision-making frameworks optimizing complex tasks in sectors such as healthcare, finance, and enterprise automation.
Other Emerging Technologies – Strategic investments in blockchain applications, data analytics platforms, and next-generation enterprise software that fit COEP Venture Group’s vision.
To learn more about COEP Venture Group and investment opportunities, visit our website https://coepventuregroup.com
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
https://finance.yahoo.com/news/coeptis-announces-launch-coep-venture-133900108.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
@coeptistx
#NEWS #AI #Marketing #Tools #Strategic #support
Trooperstocks
3 meses hace
NEWS: COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration
PR Newswire
Thu, February 6, 2025 at 8:08 AM EST 5 min read
In This Article: COEP, COEPW
WEXFORD, Pa., Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing cutting-edge technologies and artificial intelligence at the forefront of innovative biotechnology therapeutic solutions, today announced the successful closure of an additional $5.7 million in its final Series A Preferred Offering, bringing the total financing round to $10 million. This significant achievement highlights investor confidence in Coeptis' innovative therapeutic solutions and its strategic pivot towards technology-driven growth.
The financing was led by CJC Investment Trust, an entity controlled by board member Christopher Calise, through an increase in their initial investment in the round. Under the terms of the latest financing, the Series A Preferred is convertible into shares of the Company's common stock at a price of $8.00 per share, subject to limitations. Additionally, investors received an aggregate 15% equity interest in the Company's newly formed subsidiaries, SNAP Biosciences Inc. and GEAR Therapeutics Inc. This announcement follows an initial closure of $4.3 million in June 2024.
"We're thrilled to announce the successful closure of our second Series A Preferred financing," said Brian Cogley, CFO of COEPTIS. "This funding is pivotal as we expand our operational capabilities and enhance shareholder value through our new Technology Division. The integration of AI-driven tools, particularly from our recent acquisition of the NexGenAI Affiliates Network platform, is vital in revolutionizing our approach to marketing and operational efficiencies in the highly regulated biopharmaceutical sector."
The proceeds from this financing will be utilized to strengthen the Company's balance sheet, repay outstanding obligations, and support general corporate purposes, alongside the $4.3 million already raised. Moreover, the additional capital will accelerate Coeptis' ongoing integration of advanced AI solutions and automation capabilities, enhancing not only research processes but also the overall operational framework of the Company.
"This additional financing enables Coeptis to not just fortify its mission in cell therapy but also empowers us to drive innovation in technology and AI," added Dave Mehalick, President and CEO of COEPTIS. "By fostering a culture of responsible innovation, we aim to capitalize on diverse growth opportunities, creating a self-sustaining business model that establishes a strong foundation for long-term success and profitability."
About COEPTIS, Inc.
COEPTIS, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. COEPTIS is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, COEPTIS has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, COEPTIS is dedicated to advancing its mission within the regulatory framework set forth by the FDA, ensuring that all activities align with the highest standards of compliance and patient care. For more information on COEPTIS, visit https://coeptistx.com
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.
Contacts
IR@coeptistx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-completes-10-million-series-a-preferred-financing-round-reinforcing-commitment-to-technological-innovation-and-ai-integration-302369957.html
SOURCE Coeptis Pharmaceuticals, Inc.
Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
makinezmoney
1 semana hace
Monksdream
1 semana hace
Hot Features
Premium
